Measles antibodies and ?-? light chain distribution in immunoglobulins of patients affected with multiple sclerosis

1979 ◽  
Vol 220 (2) ◽  
pp. 105-112 ◽  
Author(s):  
F. Bollengier ◽  
A. Mahler
Keyword(s):  
Multiple Sclerosis ◽  
Light Chain ◽  
Measles Antibodies ◽  
Light Chain Distribution

Multiple sclerosis: Oligoclonal IgG, ξ-λ light chain distribution and measles antibodies in brain extracts

1978 ◽  
Vol 152 (1) ◽  
pp. 133-144 ◽  
Author(s):  
Francine Bollengier ◽  
Antoinette Mahler ◽  
Gaston Clinet ◽  
Armand Lowenthal
Keyword(s):  
Multiple Sclerosis ◽  
Light Chain ◽  
Measles Antibodies ◽  
Brain Extracts ◽  
Λ Light Chain ◽  
Oligoclonal Igg ◽  
Light Chain Distribution

scholarly journals Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case–control studies

2019 ◽  
Vol 90 (9) ◽  
pp. 1059-1067 ◽  
Author(s):  
Sarah-Jane Martin ◽  
Sarah McGlasson ◽  
David Hunt ◽  
James Overell
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Light Chain ◽  
Meta Analysis ◽  
Grey Literature ◽  
Case Control ◽  
Disease Stage ◽  
Case Control Studies ◽  
Neurofilament Light Chain ◽  
Neurofilament Light

ObjectiveNeurofilament is a biomarker of axonal injury proposed as a useful adjunct in the monitoring of patients with multiple sclerosis (MS). We conducted a systematic review and meta-analysis of case–control studies that have measured neurofilament light chain (NfL) levels in cerebrospinal fluid (CSF) of people with MS (pwMS), in order to determine whether, and to what degree, CSF NfL levels differentiate MS from controls, or the subtypes or stages of MS from each other.MethodsGuidelines on Preferred Reporting Items for Systematic Reviews and Meta-Analyses were followed. Electronic databases were searched for published and ‘grey’ literature, with 151 hits. Of 51 full articles screened, 20 were included in qualitative analysis, and 14 in meta-analysis.ResultsCSF NfL was higher in 746 pwMS than 435 (healthy and disease) controls, with a moderate effect size of 0.61 (p < 0.00001). Mean CSF NfL levels were significantly higher in 176 pwMS with relapsing disease than 92 with progressive disease (2124.8 ng/L, SD 3348.9 vs 1121.4 ng/L, SD 947.7, p = 0.0108). CSF NfL in 138 pwMS in relapse (irrespective of MS subtype) was double that seen in 268 pwMS in remission (3080.6 ng/L, SD 4715.9 vs 1541.7 ng/L, SD 2406.5, p < 0.0001).ConclusionsCSF NfL correlates with MS activity throughout the course of MS, reflecting the axonal damage in pwMS. Relapse is more strongly associated with elevated CSF NfL levels than the development of progression, and NfL may be most useful as a marker of disease ‘activity’ rather than as a marker of disability or disease stage.

Sign in / Sign up

Export Citation Format

Share Document